RxDoctor Payments DataLook up a doctor →

Kamran Ayub, MD

Gastroenterology · Oak Lawn, ILNPI 1942317243

Payments from drug & device makers

$4,305,514in general payments, 2019–2025

Across 854 payments — averaging $5041.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$3M
  • Capsovision, Inc.$344K
  • Ironwood Pharmaceuticals, Inc$253K
  • Braintree Laboratories, Inc.$192K
  • Bristol Myers Squibb$190K
  • AbbVie$43K
  • plus $275K from 46 others
$165,720in research payments, 2019–2025

Across 7 payments — averaging $23,674 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Laborie Medical Technologies Corp.$143K
  • Ambu A/s$22K

What the payments were for

  • Consulting fees$106,46340%
  • Speaking & faculty fees$115,69643%
  • Grants$1,5631%
  • Travel & lodging$26,29310%
  • Food & beverage$15,8456%
  • Education$470%
  • Entertainment$640%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,305,514 in reported general payments places this provider in the 95th percentile of 787 gastroenterology providers in Illinois.

See all gastroenterology providers in Illinois

Medicare billing

Part B allowed, 2024
$616,866
Medicare patients
1,183
Services billed
4,449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase11$33,123
LinzessLinaclotide12$13,082
Ursodiol18$1,728
Pantoprazole Sodium114$1,724
Omeprazole55$832
Esomeprazole Magnesium11$580
Famotidine20$343
Sucralfate17$340
Ondansetron OdtOndansetron16$306
Dicyclomine Hcl16$185
Metoclopramide Hcl74$59
Tramadol Hcl12$29

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aimmune Therapeutics, Inc.Zenpep$31,955$33,12311 claims
AbbVieLinzess$42,874$13,08212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 787 gastroenterology providers in Illinois.

Other gastroenterology in Oak Lawn

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →